Drug Shortage Report for CEFTAZIDIME FOR INJECTION, USP
| Report ID | 158756 |
| Drug Identification Number | 00886971 |
| Brand name | CEFTAZIDIME FOR INJECTION, USP |
| Common or Proper name | Ceftazidime for Injection, USP |
| Company Name | FRESENIUS KABI CANADA LTD |
| Market Status | MARKETED |
| Active Ingredient(s) | CEFTAZIDIME |
| Strength(s) | 1G |
| Dosage form(s) | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 20mL |
| ATC code | J01DD |
| ATC description | OTHER BETA-LACTAM ANTIBACTERIALS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2022-04-30 |
| Actual start date | 2022-04-30 |
| Estimated end date | 2022-06-01 |
| Actual end date | 2022-05-19 |
| Shortage status | Resolved |
| Updated date | 2022-05-24 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v7 | 2022-05-24 | French | Compare |
| v6 | 2022-05-24 | English | Compare |
| v5 | 2022-05-01 | English | Compare |
| v4 | 2022-04-25 | French | Compare |
| v3 | 2022-04-25 | English | Compare |
| v2 | 2022-04-13 | French | Compare |
| v1 | 2022-04-13 | English | Compare |
Showing 1 to 7 of 7